Actively Recruiting
Phase 2 Study of Subcutaneous OPT101 for Adults Aged 18 to 50 With Recent Onset Type 1 Diabetes
Led by Op-T LLC · Updated on 2026-04-06
72
Participants Needed
5
Research Sites
115 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety, pharmacokinetics, and early efficacy of the drug OPT101 in adults diagnosed with type 1 diabetes mellitus. The study is divided into multiple parts to assess different dosing levels and treatment durations for patients diagnosed within varying timeframes, with a focus on those diagnosed within the last 20 years and having specific C-peptide levels. It is a phase 2, randomized, triple-blind, multicenter controlled trial sponsored by Op-T LLC. The study begins with Part A, an open-label phase where three groups of six participants each receive increasing doses of OPT101 1.0, 1.5, or 2.0 mgkg administered by subcutaneous injection three times weekly for two weeks. In Part B, the highest tolerated dose from Part A will be tested over 48 weeks in 27 subjects randomized 21 to receive either OPT101 or placebo. Part C is an optional extension with another 27 subjects treated over one year using the same dosing and randomization scheme. Participants will be monitored through continuous glucose monitoring and a series of laboratory tests including measurement of C-peptide levels, pharmacokinetic parameters like maximum concentration and half-life, as well as safety assessments. The primary outcome is the change in C-peptide after 48 weeks. The study includes assessments of drug tolerance, immune cell profiles, and other health parameters, with participant involvement lasting up to one year depending on the trial part. Safety and efficacy data will be collected throughout the study period ending in 2028.
CONDITIONS
Brief Title
Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
Research Team
L
Lisa Boswell
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here